Laboratory Corporation of America Holdings (LH) has been in the news for various market activities. Analysts have been bullish on the firm with favorable projections regarding its earnings with a consistent outperformance of estimates. The firm has successfully priced $2 billion in senior notes, strengthening its financial position for future investments. Also, LH announced impressive Q1 and Q2 2024 earnings calls. Invitae's select assets were acquired by LH on a winning bid, entering into an agreement for the sale of business. This shows a strategic growth approach with acquisitions that are geared towards reinforcing its testing capacity, as shown with the further purchase of BioReference Health's diagnostic assets. LH is investing heavily in its future, striving to boost its clinical diagnostics capabilities via strategic alliances. Other key highlights include a declaration of a quarterly dividend and an increase in the price target of its stock to $282.00. However, its Q4 2023 and Q4 2024 full-year results were mixed, leaving investors with varied opinions. Following the bankruptcy of genetic test maker Invitae, LH recently announced the purchase for $239 million, demonstrating strategic insight and a propensity for risk-taking.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 23 Jun 2009 07:00:00 GMT to Fri, 20 Sep 2024 12:28:30 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -2
